Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers
Although fatigue is a common symptom in multiple sclerosis (MS), its pathomechanisms are incompletely understood. Glatiramer acetate (GA), an immunomodulatory agent approved for treatment of relapsing-remitting MS (RRMS), possesses unique mechanisms of action and has been shown to exhibit beneficial...
Main Authors: | Oliver Neuhaus, Wolfgang Köhler, Florian Then Bergh, Wolfgang Kristoferitsch, Jürgen Faiss, Thorsten Rosenkranz, Dirk Reske, Robert Patejdl, Hans-Peter Hartung, Uwe K. Zettl |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/11/3/393 |
Similar Items
-
Inconsistent Effects of Glatiramer Acetate Treatment in the 5xFAD Mouse Model of Alzheimer’s Disease
by: Berke Karaahmet, et al.
Published: (2023-06-01) -
Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01) -
Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01) -
Glatiramer acetate 40 mg/ml: A review of the results of GALA and GLACIER clinical studies
by: N. Yu. Lashch, et al.
Published: (2016-07-01) -
A case of acute invasive fungal sinusitis in an immunocompetent patient on glatiramer acetate therapy
by: Melanie Hicks, et al.
Published: (2023-12-01)